Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMLX Amylyx Pharmaceuticals	$9.38 -0.4%	$7.77	$2.08 ▼ $9.72	$839.96M	-0.46	1.19 million shs	1.68 million shs
HRTX Heron Therapeutics	$1.35 -2.9%	$1.79	$1.04 ▼ $2.68	$213.08M	1.15	2.57 million shs	1.14 million shs
NGNE Neurogene	$18.48 -1.9%	$20.38	$6.88 ▼ $74.49	$268.88M	1.69	111,648 shs	94,969 shs
OSTX OS Therapies	$2.39 +5.8%	$1.88	$1.12 ▼ $7.00	$76.22M	N/A	740,776 shs	444,948 shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMLX Amylyx Pharmaceuticals	-0.32%	+11.74%	+18.49%	+80.11%	+350.72%
HRTX Heron Therapeutics	+2.21%	+5.30%	-24.86%	-26.46%	-27.98%
NGNE Neurogene	-4.32%	-4.61%	-10.29%	+9.47%	-47.30%
OSTX OS Therapies	-9.60%	-5.83%	+23.50%	+47.71%	-37.91%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AMLX Amylyx Pharmaceuticals	3.4578 of 5 stars	4.5	2.0	0.0	2.7	2.5	0.6
HRTX Heron Therapeutics	4.0128 of 5 stars	3.2	1.0	4.2	2.8	3.3	0.6
NGNE Neurogene	2.3167 of 5 stars	3.4	0.0	0.0	3.4	1.7	1.3
OSTX OS Therapies	2.1621 of 5 stars	3.6	0.0	0.0	2.5	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMLX Amylyx Pharmaceuticals	3.00	Buy	$12.25	30.60% Upside
HRTX Heron Therapeutics	2.33	Hold	$4.50	233.33% Upside
NGNE Neurogene	2.75	Moderate Buy	$46.17	149.82% Upside
OSTX OS Therapies	3.25	Buy	$18.00	653.14% Upside

Current Analyst Ratings Breakdown

Latest OSTX, HRTX, AMLX, and NGNE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/28/2025	AMLX Amylyx Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$10.00 ➝ $14.00
8/27/2025	OSTX OS Therapies	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
8/20/2025	OSTX OS Therapies	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
8/12/2025	HRTX Heron Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong Sell
8/8/2025	HRTX Heron Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$4.00 ➝ $3.00
8/7/2025	OSTX OS Therapies	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
7/14/2025	OSTX OS Therapies	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
7/10/2025	AMLX Amylyx Pharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$10.00
6/30/2025	OSTX OS Therapies	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
6/24/2025	AMLX Amylyx Pharmaceuticals	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Hold
6/24/2025	AMLX Amylyx Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold

(Data available from 8/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMLX Amylyx Pharmaceuticals	$87.37M	9.57	N/A	N/A	$1.88 per share	4.99
HRTX Heron Therapeutics	$144.29M	1.43	N/A	N/A	($0.18) per share	-7.50
NGNE Neurogene	$930K	283.56	N/A	N/A	$19.15 per share	0.97
OSTX OS Therapies	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMLX Amylyx Pharmaceuticals	-$301.74M	-$2.50	N/A	N/A	N/A	N/A	-82.48%	-70.15%	11/6/2025 (Estimated)
HRTX Heron Therapeutics	-$13.58M	-$0.02	N/A	N/A	N/A	-0.62%	N/A	-0.40%	11/11/2025 (Estimated)
NGNE Neurogene	-$75.14M	-$4.31	N/A	N/A	N/A	N/A	-33.33%	-30.34%	11/17/2025 (Estimated)
OSTX OS Therapies	-$7.79M	-$0.79	N/A	N/A	N/A	N/A	N/A	-569.57%	N/A

Latest OSTX, HRTX, AMLX, and NGNE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2025	Q2 2025	NGNE Neurogene	-$1.15	-$1.05	+$0.10	-$1.05	N/A	N/A
8/8/2025	Q2 2025	HRTX Heron Therapeutics	-$0.01	-$0.02	-$0.01	-$0.02	$38.08 million	$37.20 million
8/7/2025	Q2 2025	AMLX Amylyx Pharmaceuticals	-$0.44	-$0.46	-$0.02	-$0.46	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMLX Amylyx Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
HRTX Heron Therapeutics	N/A	N/A	N/A	N/A	N/A
NGNE Neurogene	N/A	N/A	N/A	N/A	N/A
OSTX OS Therapies	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMLX Amylyx Pharmaceuticals	N/A	8.72	8.72
HRTX Heron Therapeutics	N/A	0.82	0.53
NGNE Neurogene	N/A	18.07	18.07
OSTX OS Therapies	N/A	0.76	0.76

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AMLX Amylyx Pharmaceuticals	95.84%
HRTX Heron Therapeutics	80.01%
NGNE Neurogene	52.37%
OSTX OS Therapies	N/A

Insider Ownership

Company	Insider Ownership
AMLX Amylyx Pharmaceuticals	12.30%
HRTX Heron Therapeutics	5.86%
NGNE Neurogene	11.64%
OSTX OS Therapies	13.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AMLX Amylyx Pharmaceuticals	200	89.17 million	78.20 million	Optionable
HRTX Heron Therapeutics	300	153.29 million	144.31 million	Optionable
NGNE Neurogene	90	14.27 million	12.61 million	Optionable
OSTX OS Therapies	N/A	31.89 million	N/A	N/A

OSTX, HRTX, AMLX, and NGNE Headlines

Recent News About These Companies

D. Boral Capital Reiterates "Buy" Rating for OS Therapies (NYSE:OSTX)

August 29 at 8:41 AM | marketbeat.com

OS Therapies to Provide OST-HER2 Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma FDA End of Phase 2 Meeting Update on Tuesday, September 2, 2025

August 27 at 4:01 PM | newsfilecorp.comN

OS Therapies Ends Equity Agreement with Square Gate

August 26 at 6:50 AM | tipranks.com

OS Therapies Reports Progress in Osteosarcoma Treatment

August 25, 2025 | tipranks.com

OS Therapies Terminates Equity Line of Credit

August 25, 2025 | newsfilecorp.comN

OS Therapies (NYSE:OSTX) Earns "Buy" Rating from D. Boral Capital

August 22, 2025 | marketbeat.com

OS Therapies Inc Reports Q2 2025 Earnings: Net Loss Per Share at $0.19, Revenue Details Unavailable

August 19, 2025 | gurufocus.com

OS Therapies Reports Second Quarter 2025 Financial Results and Provides Business Update

August 19, 2025 | newsfilecorp.comN

Earnings Outlook For OS Therapies

August 18, 2025 | benzinga.com

OS Therapies Updates Quorum Rules for Shareholder Meetings

August 15, 2025 | tipranks.com

OS Therapies Delays Q2 2025 Financial Report

August 15, 2025 | tipranks.com

OS Therapies to Report Second Quarter 2025 Financial Results and Provide Business Update on Tuesday, August 19th, 2025

August 14, 2025 | newsfilecorp.comN

OS Therapies Announces Statistically Significant Positive Interim 2-Year Overall Survival Data from Phase 2b Clinical Trial of OST-HER2 in the Prevention or Delay of Recurrent ...

August 9, 2025 | finance.yahoo.com

OS Therapies Receives Positive Feedback from UK MHRA Scientific Advice Meeting and Submits Innovative Licensing and Access Pathway (ILAP) Request for OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma

August 7, 2025 | newsfilecorp.comN

OS Therapies files to sell 3.76M shares of common stock for holders

August 6, 2025 | msn.com

OS Therapies Inc News (OSTX) - Investing.com

July 18, 2025 | investing.com

OS Therapies Inc. (NYSE-A: OSTX) Makes Important Strides in Rare Cancer Therapy

July 14, 2025 | theglobeandmail.com

OS Therapies Raises $4.2M Through Warrant Exercise

July 14, 2025 | tipranks.com

OS Therapies Closes $4.2 Million in Warrant Exercise Inducement and Exchange Offer

July 14, 2025 | newsfilecorp.comN

OS Therapies Inc.: Promising Cancer Immunotherapy and Strategic Regulatory Advancements Support Buy Rating

July 11, 2025 | tipranks.com

OS Therapies Provides Clinical & Global Regulatory Updates

July 10, 2025 | newsfilecorp.comN

New MarketBeat Followers Over Time

Media Sentiment Over Time

OSTX, HRTX, AMLX, and NGNE Company Descriptions

Amylyx Pharmaceuticals NASDAQ:AMLX

$9.38 -0.04 (-0.42%)

Closing price 04:00 PM Eastern

Extended Trading

$9.38 0.00 (0.00%)

As of 06:52 PM Eastern

Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Heron Therapeutics NASDAQ:HRTX

$1.35 -0.04 (-2.88%)

Closing price 04:00 PM Eastern

Extended Trading

$1.38 +0.02 (+1.85%)

As of 07:17 PM Eastern

Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.

Neurogene NASDAQ:NGNE

$18.48 -0.36 (-1.91%)

Closing price 04:00 PM Eastern

Extended Trading

$18.47 -0.01 (-0.05%)

As of 04:10 PM Eastern

Neurogene Inc., a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of North Carolina, the University of Edinburgh, Virovek, Inc., and Sigma-Aldrich Co. LLC. The company is headquartered in New York, New York.

OS Therapies NYSE:OSTX

$2.39 +0.13 (+5.75%)

Closing price 04:00 PM Eastern

Extended Trading

$2.33 -0.06 (-2.55%)

As of 08:00 PM Eastern

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time